Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

Nikoletta Lendvai,Andrew J Yee,Ioanna Tsakos,Aeri Alexander,Sean M Devlin,Hani Hassoun,Neha Korde,Alexander M Lesokhin,Heather Landau,Sham Mailankody,Guenther Koehne,David J Chung,Ola Landgren,Noopur S Raje,Sergio Giralt

Blood（2016）

引用 13|浏览26

暂无评分

摘要

To the editor:Despite the introduction of proteasome inhibitors and immunomodulatory drugs followed by autologous stem cell transplant, most patients with multiple myeloma (MM) will have disease recurrence after primary therapy. Thus, agents with different mechanisms of action and different

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要